跳至主要内容
临床试验/CTIS2024-511390-30-00
CTIS2024-511390-30-00招募中1 期

Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Cream (Test) vs. Advantan(R) 0.1% Cream (Reference) vs. Vehicle in patients with mild to moderate atopic dermatitis - 22-01/MPA-C

Dermapharm AG0 个研究点目标入组 330 人开始时间: 2024年5月14日最近更新:

试验速览

阶段
1 期
状态
招募中
发起方
Dermapharm AG
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 65+(—)
性别
All

入选标准

  • Women, men and children/adolescents of both sexes = 6 years of age, Written consent to study participation after patient information by the investigator, In case of patients below the age of 18: Written consent to study participation of legal guardian(s) and child/adolescent patient after an age-appropriate patient- and legal guardian(s)- information session by the investigator, Acute flare of atopic dermatitis according to the Investigator´s Global Assessment (IGA score 2 (mild) or 3 (moderate)), Affected body surface (BSA) between at least 10% and not more than 40%, For women of childbearing potential: Application of an established highly efficient contraceptive method during the whole study, For all female patients of childbearing potential: Urine pregnancy test

排除标准

  • Any systemic treatment of the atopic dermatitis within the last 4 weeks prior to study inclusion, Other concomitant diseases which may - taking the present knowledge into account - influence the parameters evaluated in the study in a way that an objective evaluation would be impossible, Other concomitant medication which may - taking the present knowledge into account - influence the methods of measurement used in this study or the resulting data, Reasonable doubt concerning the co-operation of the patient, Participation in another clinical study within the last 30 days prior to inclusion in this study, Participation in this study at an earlier date, Women with existing or intended pregnancy or during lactation, Any topical treatment (e.g. topical immunomodulators such as tacrolimus ointment, pimecrolimus cream, topical antibiotics, topical glucocorticoids, other topical anti-inflammatory medication) or physical therapy (e.g. UV radiation) of the atopic dermatitis in the test area 2 weeks prior to study inclusion, Presence of tuberculous or syphilitic processes in the treatment area, Presence of viral infections (such as herpes or varicella), rosacea, perioral dermatitis, ulcera, acne vulgaris, atrophic skin diseases and vaccination skin reactions in the area to be treated., Presence of bacterial and/or mycotic skin diseases in the treatment area, Current diagnosis of glaucoma or cataract, Known intolerance or hypersensitivity against methylprednisolone aceponate or any of the other ingredients in the study medication, Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area, which would interfere with evaluations, Severe acute or chronic concomitant disease with severe impairment of the general condition

研究者

发起方
Dermapharm AG

相似试验

进行中(未招募)
1 期
Clinical study to compare two cutaneous emulsions with the active substance methylprednisolone aceponate 0.1% and one cutaneous emulsion without active substance for patients withatopic dermatitisAtopic dermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858
EUCTR2018-001743-31-DEDermapharm AG330
进行中(未招募)
1 期
Clinical study to compare the therapeutic effects of two ointments with the active substances clotrimazole and betamethasone dipropionate and of one ointment without active substance for patients with moderate to severely inflamed infection of the skin through yeast fungi.moderate to severely inflamed candidiasis of the skinMedDRA version: 20.0Level: LLTClassification code 10007159Term: Candidiasis of skin and nailsSystem Organ Class: 10021881 - Infections and infestations
EUCTR2021-003790-65-DEDermapharm AG552
进行中(未招募)
1 期
Clinical study to compare two creams with the active substance imiquimod and one cream without active substance for patients with actinic keratosisActinic keratosisMedDRA version: 20.0 Level: PT Classification code 10000614 Term: Actinic keratosis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2016-000712-15-DEDermapharm AG426
进行中(未招募)
1 期
Clinical study to compare two ointments with the active substance gentamicin and betamethason and one ointment without active substance for patients with bacterial infected eczemaBacterial infected eczemasMedDRA version: 19.1Level: PTClassification code 10014199Term: Eczema infectedSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-005519-18-DEDermapharm AG400
进行中(未招募)
1 期
Clinical study to compare two gels with the active substance calcipotriol and betamethasone and one gel without active substance for patients with scalp psoriasisPsoriasis capitisMedDRA version: 20.0Level: LLTClassification code 10037157Term: Psoriasis of scalpSystem Organ Class: 100000018190
EUCTR2016-001106-42-DEDermapharm AG225